Free Trial
NASDAQ:VSTM

Verastem Q3 2024 Earnings Report

Verastem logo
$4.71 +0.02 (+0.43%)
Closing price 04:00 PM Eastern
Extended Trading
$4.68 -0.03 (-0.64%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verastem EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.71
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Verastem Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Verastem Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Verastem's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Earnings Documents

Verastem Earnings Headlines

BTIG Remains a Buy on Verastem (VSTM)
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
See More Verastem Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verastem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verastem and other key companies, straight to your email.

About Verastem

Verastem (NASDAQ:VSTM) Oncology, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on the development and commercialization of small‐molecule therapies for the treatment of cancer. Headquartered in Boston, Massachusetts, Verastem Oncology was founded in 2010 to advance a pipeline of targeted agents designed to inhibit key signaling pathways that drive tumor growth and survival. The company’s initial success centered on duvelisib (Copiktra®), an oral PI3K‐delta/gamma inhibitor approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. Although commercial rights to Copiktra were subsequently transferred, this program laid the foundation for Verastem’s shift toward precision oncology.

Presently, Verastem Oncology’s research and development efforts are concentrated on two lead assets: VS-6766, a dual RAF/MEK inhibitor, and defactinib, a focal adhesion kinase (FAK) inhibitor. These orally administered small molecules are being evaluated both as single agents and in combination regimens across a variety of genetically defined solid tumors, including KRAS‐mutant non-small cell lung cancer, biliary tract cancer, and gynecologic malignancies. The company’s approach leverages the concept of synthetic lethality—targeting complementary pathways to maximize tumor cell death while minimizing resistance.

Verastem Oncology conducts clinical trials primarily in the United States, with select studies in Europe and Asia to ensure broad patient access and to generate data that support global regulatory submissions. The company collaborates with leading academic institutions and research consortia to identify biomarkers that predict response to therapy and to refine patient selection strategies. These partnerships aim to accelerate the path to registration and enhance the clinical benefit of Verastem’s targeted therapies.

Under the leadership of President and Chief Executive Officer Gisela Schwab, Verastem Oncology emphasizes operational discipline and scientific rigor. The management team combines expertise in oncology drug development, regulatory affairs, and commercial strategy. Guided by a multidisciplinary board of directors and seasoned advisory panels, the company continues to expand its pipeline through in‐licensing, strategic collaborations, and disciplined internal discovery programs, with the goal of delivering innovative treatment options for patients facing serious cancers.

View Verastem Profile

More Earnings Resources from MarketBeat